The Memo: Batea Oncology Taking a New Mechanical Approach to Glioblastoma

Under the direction of Sonia Martínez Arca, PhD, Batea Oncology is developing what it describes as the first mechanomedicine platform for cancer, beginning with glioblastoma, one of oncology’s deadliest and most treatment-resistant diseases. Rather than relying on traditional pharmacological approaches, the company’s implantable medical device leverages the mechanical behavior of cancer cells to capture them after surgery and improve their response to radiotherapy. As Batea Oncology prepares to begin its first-in-human clinical trial, the company is working to establish an entirely new therapeutic paradigm for solid tumors with high recurrence rates.

Origin Story

Batea Oncology was founded with a straightforward goal: translate promising laboratory discoveries into therapies capable of improving outcomes for patients facing some of oncology’s greatest unmet needs.

“Our motivation to create Batea Oncology was to translate the very promising results obtained in the lab to the patients in a real translational manner,” Martínez Arca said. “Our co-founders are linked to the Health Research Institute and the University Clinical Hospital in Santiago de Compostela, and therefore we are strongly aware of the unmet medical needs, in particular in oncology.”

Based in Santiago de Compostela, Spain, the company is initially targeting the European market while planning to expand into the United States. Its long-term ambition extends beyond a single product.

“Our vision is to become the pioneering reference company for mechanomedicine applied to low survival solid tumors,” Martínez Arca said.

The company’s first focus is glioblastoma, where decades of research have produced only modest improvements despite the disease’s devastating prognosis.

The Current Landscape

Glioblastoma remains the most common and aggressive primary brain cancer, with a median life expectancy of only 15 months. More than 240,000 new cases are diagnosed worldwide each year, and incidence continues to rise. Yet the standard treatment has remained largely unchanged since the introduction of the Stupp protocol in 2005, which combines maximal surgical resection with radiotherapy and chemotherapy.

While surgery removes the primary tumor, it cannot eliminate every cancer cell. Residual glioblastoma cells remain along the surgical margins, infiltrate healthy brain tissue, and ultimately drive recurrence. Most patients experience relapse within seven to eight months of diagnosis.

According to Martínez Arca, several biological barriers continue to limit progress. The blood-brain barrier prevents many therapies from reaching the tumor site, while glioblastoma’s highly immunosuppressive microenvironment reduces the effectiveness of both conventional drugs and newer immunotherapies. As a result, many targeted therapies that have transformed treatment in other cancers have failed to deliver meaningful survival benefits in glioblastoma.

Medical devices have emerged as another avenue of innovation, but existing technologies have also faced challenges.

“These shortcomings leave a clear unmet need for a new class of treatment: one that is focal, clinically practical, compatible with standard neurosurgical workflows, and capable of controlling the residual tumor cells that drive recurrence while preserving patients’ quality of life,” Martínez Arca said. “This is what we have developed, starting with a completely new perspective: a mechanobiology-based implantable medical device, named GlioHook.”

Inside the Innovation

At the center of Batea Oncology’s platform is GlioHook, a Class III implantable medical device built around the concept of mechanomedicine, an emerging principle in cancer biology that uses inherent mechanical properties of cancer cells as potential vulnerabilities.

Immediately following tumor resection, the device is implanted in contact with residual cancer cells. Its porous polycarbonate-polyurethane scaffold is intentionally stiffer than surrounding brain tissue.

“GlioHook exploits the natural durotaxis abilities of infiltrating tumor cells (e.g., their capacity to migrate towards stiffer substrates) to trick their migration and invasion patterns,” Martínez Arca explained.

As cancer cells sense the scaffold’s stiffness via mechanosensation, they migrate into the implant instead of continuing to invade healthy brain tissue. A bovine collagen coating encourages those cells to adhere within the device, effectively trapping them inside a localized environment.

“This creates a new therapeutic paradigm: transforming an infiltrative disease into a local and targetable niche where tumor cells can be exposed more effectively to radiotherapy and other treatments,” Martínez Arca said.

The device is designed to limit recurrence through two complementary mechanisms. First, it captures residual glioblastoma cells that would otherwise continue spreading through the brain. Second, mechanical confinement alters the biology of those trapped cells, reducing DNA repair pathways and adaptive resistance mechanisms that contribute to radioresistance, making them more sensitive to radiotherapy.

Unlike many investigational therapies, GlioHook is designed to integrate directly into existing neurosurgical workflows. It is implanted during standard surgical resection, acts during the treatment gap before radiotherapy begins, remains compatible with both current standards of care and emerging therapies such as immunotherapy, and avoids the toxicity associated with pharmacological approaches.

Progress and Milestones

Batea Oncology has now completed several important development milestones as it advances toward clinical evaluation.

The company has finalized GMP manufacturing of GlioHook and completed its regulatory preclinical package. It has also received Ethics Committee clearance to begin a first-in-human clinical trial enrolling 15 newly diagnosed glioblastoma patients, with enrollment expected to begin in the fourth quarter of 2026.

Beyond glioblastoma, Batea Oncology is expanding its mechanomedicine platform to additional tumors where complete surgical removal remains difficult, including soft tissue sarcoma. The company is also investigating combinations with immunotherapies after observing encouraging effects on the tumor immune microenvironment in preclinical studies.

To support these efforts, Batea Oncology has raised more than €3.1 million to date, including an initial Seed financing led by two venture capital firms, and is currently closing an €8.5 million Series A financing in two derisking tranches, the first one of up to €2.5 million. The funding is expected to support clinical development through early efficacy readouts, positioning the company for a pivotal clinical trial and eventual CE marking in the years ahead.

As Martínez Arca prepares to attend LSI Europe, the company is seeking strategic medtech partners and investors while introducing the mechanomedicine concept to a broader audience.

“We are looking forward to getting feedback about our first-in-concept approach to glioblastoma,” she said. “Our goals are establishing first contacts with medtech companies with potential interest in our technology, and discussing with investors their fit in our current Series A investment round.”

Join Us at LSI Europe ‘26

Martínez Arca has been selected to present at LSI Europe '26, September 28th–October 1st, in front of hundreds of global medical technology companies. Join us in welcoming her to the event in Barcelona, where she will share the latest updates on Batea Oncology’s technology and development.